Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

Inhibition of the vascular endothelial growth factor (VEGF) pathway has failed to improve overall survival of patients with glioblastoma (GBM). We previously showed that angiopoietin-2 (Ang-2) overexpression compromised the benefit from anti-VEGF therapy in a preclinical GBM model. Here we investiga...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Proc Natl Acad Sci U S A
Main Authors: Kloepper, Jonas, Riedemann, Lars, Amoozgar, Zohreh, Seano, Giorgio, Susek, Katharina, Yu, Veronica, Dalvie, Nisha, Amelung, Robin L., Datta, Meenal, Song, Jonathan W., Askoxylakis, Vasileios, Taylor, Jennie W., Lu-Emerson, Christine, Batista, Ana, Kirkpatrick, Nathaniel D., Jung, Keehoon, Snuderl, Matija, Muzikansky, Alona, Stubenrauch, Kay G., Krieter, Oliver, Wakimoto, Hiroaki, Xu, Lei, Munn, Lance L., Duda, Dan G., Fukumura, Dai, Batchelor, Tracy T., Jain, Rakesh K.
פורמט: Artigo
שפה:Inglês
יצא לאור: National Academy of Sciences 2016
נושאים:
Biological Sciences
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4843473/
https://ncbi.nlm.nih.gov/pubmed/27044098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1525360113
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים